Geode Capital Management, LLC Revance Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

$1.12 Trillion
Q2 2024

A detailed history of Geode Capital Management, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,297,965 shares of RVNC stock, worth $5.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,297,965

Previous 1,970,838 16.6%

Holding current value

$5.91 Million

Previous $9.7 Million 39.1%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$2.34 - $4.73 $765,477 - $1.55 Million	327,127 Added 16.6%	2,297,965 $5.91 Million
Q1 2024 May 13, 2024	BUY	$4.65 - $9.31 $215,839 - $432,142	46,417 Added 2.41%	1,970,838 $9.7 Million
Q4 2023 Feb 13, 2024	BUY	$5.81 - $11.2 $837,476 - $1.61 Million	144,144 Added 8.1%	1,924,421 $16.9 Million
Q3 2023 Nov 13, 2023	BUY	$11.47 - $25.07 $972,277 - $2.13 Million	84,767 Added 5.0%	1,780,277 $20.4 Million
Q2 2023 Aug 11, 2023	BUY	$24.7 - $37.61 $2.45 Million - $3.72 Million	98,996 Added 6.2%	1,695,510 $42.9 Million
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $1.14 Million - $2.19 Million	62,069 Added 4.05%	1,596,514 $51.4 Million
Q4 2022 Feb 13, 2023	BUY	$18.32 - $30.66 $2.77 Million - $4.64 Million	151,204 Added 10.93%	1,534,445 $28.3 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $2.1 Million - $4.16 Million	146,289 Added 11.83%	1,383,241 $37.3 Million
Q2 2022 Aug 12, 2022	SELL	$11.52 - $20.4 $1.14 Million - $2.02 Million	-99,239 Reduced 7.43%	1,236,952 $17.1 Million
Q1 2022 May 13, 2022	BUY	$12.36 - $20.31 $298,011 - $489,694	24,111 Added 1.84%	1,336,191 $26.1 Million
Q4 2021 Feb 11, 2022	BUY	$12.46 - $27.87 $1.34 Million - $3 Million	107,692 Added 8.94%	1,312,080 $21.4 Million
Q3 2021 Nov 12, 2021	BUY	$25.78 - $33.21 $14,875 - $19,162	577 Added 0.05%	1,204,388 $33.6 Million
Q2 2021 Aug 13, 2021	BUY	$26.8 - $31.84 $2.23 Million - $2.65 Million	83,303 Added 7.43%	1,203,811 $35.7 Million
Q1 2021 May 12, 2021	BUY	$24.03 - $29.97 $3.09 Million - $3.85 Million	128,414 Added 12.94%	1,120,508 $31.3 Million
Q4 2020 Feb 12, 2021	BUY	$23.41 - $28.34 $1.2 Million - $1.46 Million	51,418 Added 5.47%	992,094 $28.1 Million
Q3 2020 Nov 13, 2020	BUY	$23.23 - $34.3 $3.33 Million - $4.91 Million	143,224 Added 17.96%	940,676 $23.6 Million
Q2 2020 Aug 13, 2020	BUY	$12.6 - $26.55 $927,133 - $1.95 Million	73,582 Added 10.17%	797,452 $19.5 Million
Q1 2020 May 14, 2020	BUY	$12.46 - $27.81 $1.7 Million - $3.8 Million	136,718 Added 23.28%	723,870 $10.7 Million
Q4 2019 Feb 13, 2020	BUY	$11.66 - $20.15 $115,387 - $199,404	9,896 Added 1.71%	587,152 $9.53 Million
Q3 2019 Nov 12, 2019	BUY	$10.22 - $14.5 $164,971 - $234,059	16,142 Added 2.88%	577,256 $7.5 Million
Q2 2019 Aug 14, 2019	BUY	$10.67 - $15.49 $776,423 - $1.13 Million	72,767 Added 14.9%	561,114 $7.28 Million
Q1 2019 May 14, 2019	BUY	$15.4 - $20.39 $1.58 Million - $2.09 Million	102,529 Added 26.57%	488,347 $7.7 Million
Q4 2018 Feb 13, 2019	BUY	$18.06 - $24.96 $872,749 - $1.21 Million	48,325 Added 14.32%	385,818 $7.77 Million
Q3 2018 Nov 13, 2018	BUY	$23.55 - $30.1 $786,664 - $1.01 Million	33,404 Added 10.98%	337,493 $8.39 Million
Q2 2018 Aug 14, 2018	BUY	$27.45 - $33.35 $1.14 Million - $1.39 Million	41,697 Added 15.89%	304,089 $8.35 Million
Q1 2018 May 15, 2018	BUY	$29.15 - $37.4 $1.25 Million - $1.6 Million	42,831 Added 19.51%	262,392 $8.08 Million
Q4 2017 Feb 13, 2018	BUY	$24.55 - $36.3 $406,081 - $600,438	16,541 Added 8.15%	219,561 $7.85 Million
Q3 2017 Nov 14, 2017	BUY	$22.55 - $28.1 $250,958 - $312,724	11,129 Added 5.8%	203,020 $5.59 Million
Q2 2017 Aug 14, 2017	BUY	N/A	191,891	191,891 $5.07 Million

Others Institutions Holding RVNC

# of Institutions

204

Shares Held

84.3M

Call Options Held

490K

Put Options Held

147K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Revance Therapeutics, Inc. Transaction History